Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18483370rdf:typepubmed:Citationlld:pubmed
pubmed-article:18483370lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0376545lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:18483370lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:18483370pubmed:issue10lld:pubmed
pubmed-article:18483370pubmed:dateCreated2008-5-16lld:pubmed
pubmed-article:18483370pubmed:abstractTextCT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies.lld:pubmed
pubmed-article:18483370pubmed:languageenglld:pubmed
pubmed-article:18483370pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:citationSubsetIMlld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18483370pubmed:statusMEDLINElld:pubmed
pubmed-article:18483370pubmed:monthMaylld:pubmed
pubmed-article:18483370pubmed:issn1078-0432lld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:NaglerArnonAlld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:ShimoniAvicha...lld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:Rotem-Yehudar...lld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:KnellerAbraha...lld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:BergerRaananRlld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:Koren-Michowi...lld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:LeibaMeravMlld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:SlamaGideonGlld:pubmed
pubmed-article:18483370pubmed:authorpubmed-author:LandesShimonSlld:pubmed
pubmed-article:18483370pubmed:issnTypePrintlld:pubmed
pubmed-article:18483370pubmed:day15lld:pubmed
pubmed-article:18483370pubmed:volume14lld:pubmed
pubmed-article:18483370pubmed:ownerNLMlld:pubmed
pubmed-article:18483370pubmed:authorsCompleteYlld:pubmed
pubmed-article:18483370pubmed:pagination3044-51lld:pubmed
pubmed-article:18483370pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:meshHeadingpubmed-meshheading:18483370...lld:pubmed
pubmed-article:18483370pubmed:year2008lld:pubmed
pubmed-article:18483370pubmed:articleTitlePhase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.lld:pubmed
pubmed-article:18483370pubmed:affiliationInstitute of Oncology and Radiotherapy, Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.lld:pubmed
pubmed-article:18483370pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18483370pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18483370lld:pubmed